These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 21496012)
41. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678 [TBL] [Abstract][Full Text] [Related]
42. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123 [TBL] [Abstract][Full Text] [Related]
43. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date. Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964 [TBL] [Abstract][Full Text] [Related]
44. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
45. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
46. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms. Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122 [TBL] [Abstract][Full Text] [Related]
47. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Middlemas DS; Stewart CF; Kirstein MN; Poquette C; Friedman HS; Houghton PJ; Brent TP Clin Cancer Res; 2000 Mar; 6(3):998-1007. PubMed ID: 10741727 [TBL] [Abstract][Full Text] [Related]
48. High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. Takeshita A; Inoshita N; Taguchi M; Okuda C; Fukuhara N; Oyama K; Ohashi K; Sano T; Takeuchi Y; Yamada S Eur J Endocrinol; 2009 Oct; 161(4):553-9. PubMed ID: 19589911 [TBL] [Abstract][Full Text] [Related]
49. O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. Jiang X; Reardon DA; Desjardins A; Vredenburgh JJ; Quinn JA; Austin AD; Herndon JE; McLendon RE; Friedman HS J Neurooncol; 2013 Aug; 114(1):135-40. PubMed ID: 23686298 [TBL] [Abstract][Full Text] [Related]
50. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. Aghi M; Rabkin S; Martuza RL J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370 [TBL] [Abstract][Full Text] [Related]
51. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Zauderer MG; Drilon A; Kadota K; Huberman K; Sima CS; Bergagnini I; Sumner DK; Travis WD; Heguy A; Ginsberg MS; Holodny AI; Riely GJ; Kris MG; Krug LM; Pietanza MC Lung Cancer; 2014 Nov; 86(2):237-40. PubMed ID: 25194640 [TBL] [Abstract][Full Text] [Related]
52. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. McCormack A; Dekkers OM; Petersenn S; Popovic V; Trouillas J; Raverot G; Burman P; Eur J Endocrinol; 2018 Mar; 178(3):265-276. PubMed ID: 29330228 [TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172 [TBL] [Abstract][Full Text] [Related]
55. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Batisse M; Raverot G; Maqdasy S; Durando X; Sturm N; Montoriol PF; Kemeny JL; Chazal J; Trouillas J; Tauveron I Cancer Invest; 2013 Mar; 31(3):190-6. PubMed ID: 23477586 [TBL] [Abstract][Full Text] [Related]
56. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. Curtò L; Torre ML; Ferraù F; Pitini V; Altavilla G; Granata F; Longo M; Hofland LJ; Trimarchi F; Cannavò S ScientificWorldJournal; 2010 Nov; 10():2132-8. PubMed ID: 21057727 [TBL] [Abstract][Full Text] [Related]
57. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution. Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749 [TBL] [Abstract][Full Text] [Related]